Bidding price of 93 key products and exposure of purchasing volume of medical institutions

With the disclosure of the annual report of Listed Companies in 2018, more and more top 10 billion revenue households have emerged As of April 15, there were 14 pharmaceutical enterprises with a revenue of more than 10 billion yuan, including Hengrui pharmaceutical, Fosun Pharmaceutical and Shanghai pharmaceutical, which disclosed the bid price of key products and the total actual purchase volume of medical institutions Bid winning situation of SHP in drug centralized bidding and purchase the highest bid price of some drugs of SHP in 2018 decreased to varying degrees, but it had no significant impact on the overall sales According to the data, Shanghai Pharmaceutical's industrial sales network covers 31 provinces, regions and municipalities directly under the central government, and its customers include various medical institutions, pharmaceutical commercial companies and pharmacies The company mainly adopts the sales mode of "self operation + investment promotion agent" to achieve the coverage of National Hospital terminals and retail terminals through the sales channels of dealers or agents In addition, the pricing principle of prescription drug products is determined by the bid price of each province; OTC products and health care products are determined by the price system formed by market competition Bid winning of Baiyunshan in centralized drug bidding and procurement Baiyunshan's main business is composed of four parts, i.e Dayan pharmaceutical, big business, big health and big medical treatment Among them, Danan pharmaceutical is mainly engaged in the R & D and manufacturing of Chinese and Western patent medicines, chemical APIs, biomedicine and natural medicines Its sales mode is self-supporting and agency mode, mainly through dealers and agents at all levels to cover most hospitals, community medical and retail terminals nationwide Among them, according to the relevant national policies, the bidding products of hospitals are tendered nationwide, and the relevant drugs are distributed after winning the bid; the non hospital bidding products are mainly promoted through the agency and distribution mode The bid winning situation of China Pharmaceutical in the centralized bidding and purchase of drugs China Pharmaceutical said that the bid winning price of provincial bidding in 2018 was unchanged from that in 2017 Due to the time difference between the formal implementation time and the actual purchase after winning the bid, the total actual purchase volume of the medical institutions listed in the above table is the actual external sales volume of the company The procurement mode of all regions is developing in a diversified trend The company actively studies and implements policies of all regions to ensure the bid winning rate of key products in important provinces The bid winning situation of Fosun Pharmaceutical in the centralized bidding and purchase of drugs Fosun Pharmaceutical said that the centralized bidding and purchase of drugs ushered in a turning point in 2018 The implementation of volume purchase not only compresses the intermediate links of drug circulation, reduces drug prices and saves medical insurance costs, but also reserves policy space for innovative drugs to enter the market and patients to benefit Fosun Pharmaceutical has been focusing on its investment since the early stage of policy-making on volume procurement Meanwhile, combined with the policy trend, according to the characteristics of a single variety and the competition pattern, "one product, one policy" to sort out the key products and formulate the response plan Focus on the consistency evaluation and pharmaceutical innovation of generic drugs, increase efforts to promote and enhance the core competitiveness of the company's products Fosun Pharmaceutical continues to strengthen the construction of domestic and foreign marketing system, and has formed a domestic and foreign marketing team of nearly 5300 people, including more than 1000 overseas marketing teams In terms of domestic marketing, it mainly adopts the sales mode of combination of self operation and agency; in terms of international marketing, it will build a marketing platform in the United States and Europe in the future to cooperate with the existing international marketing channels, improve the international marketing platform of drugs, and improve the scale of drug sales in the international market The sales business of Hengrui pharmaceutical in China is mainly in the charge of the holding subsidiary Jiangsu Kexin Pharmaceutical Sales Co., Ltd (hereinafter referred to as Jiangsu Kexin) and the wholly-owned subsidiary Jiangsu Xinchen Pharmaceutical Co., Ltd (hereinafter referred to as Jiangsu Xinchen) Jiangsu Kexin, a holding subsidiary, is mainly engaged in the wholesale sales of anti-tumor drugs, special infusion, contrast agents and cardiovascular drugs produced by the company itself (including Shanghai Hengrui), and some agents sell drug loaded microspheres (medical intervention equipment) of Suzhou Hengrui jialisheng Biomedical Technology Co., Ltd (the holding subsidiary of Jiangsu Hengrui Pharmaceutical Group Co., Ltd., the controlling shareholder of the company) Jiangsu Xinchen is mainly engaged in the wholesale sales of the company's self-produced surgical anesthetics The provincial drug bidding takes price reduction as the leading idea, the policy of second price negotiation and linkage of the lowest price is frequent, and the "4 + 7" drug centralized procurement pilot program is implemented Hengrui pharmaceutical said it will accelerate the transformation and upgrading, improve the innovation ability and level, and accelerate the listing of innovative drugs At the same time, adhere to the management policy of "quality first", increase hardware and software investment, strive to make the main varieties pass the certification of European and American mainstream countries, so that the generic drugs can truly achieve the quality of imported similar products, and have the ability to compete with international products The bid winning situation of Harbin Pharmaceutical Co., Ltd in the centralized bidding and purchase of drugs, said that the bid winning of the above drugs solved the market access problem of the company's products in the medical institutions in the bidding area, and was conducive to improving the company's product sales and market share The pricing principles of its main products in the end market are: the pricing of prescription drug products by government bidding; the pricing system of OTC products and health care products by market competition.